Literature DB >> 21528055

Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis.

Valeria D'Ovidio1, Donatella Meo, Angelo Viscido, Giampaolo Bresci, Piero Vernia, Renzo Caprilli.   

Abstract

AIM: To identify factors predicting the clinical response of ulcerative colitis patients to granulocyte-monocyte apheresis (GMA).
METHODS: Sixty-nine ulcerative colitis patients (39 F, 30 M) dependent upon/refractory to steroids were treated with GMA. Steroid dependency, clinical activity index (CAI), C reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), values at baseline, use of immunosuppressant, duration of disease, and age and extent of disease were considered for statistical analysis as predictive factors of clinical response. Univariate and multivariate logistic regression models were used.
RESULTS: In the univariate analysis, CAI (P = 0.039) and ESR (P = 0.017) levels at baseline were singled out as predictive of clinical remission. In the multivariate analysis steroid dependency [Odds ratio (OR) = 0.390, 95% Confidence interval (CI): 0.176-0.865, Wald 5.361, P = 0.0160] and low CAI levels at baseline (4 < CAI < 7) (OR = 0.770, 95% CI: 0.425-1.394, Wald 3.747, P = 0.028) proved to be effective as factors predicting clinical response.
CONCLUSION: GMA may be a valid therapeutic option for steroid-dependent ulcerative colitis patients with mild-moderate disease and its clinical efficacy seems to persist for 12 mo.

Entities:  

Keywords:  Granulocyte-monocyte apheresis; Long-term follow-up; Predictive factors; Steroid therapy; Ulcerative colitis

Mesh:

Substances:

Year:  2011        PMID: 21528055      PMCID: PMC3080717          DOI: 10.3748/wjg.v17.i14.1831

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis.

Authors:  Wolfgang Kruis; Axel Dignass; Elisabeth Steinhagen-Thiessen; Julia Morgenstern; Joachim Mössner; Stephan Schreiber; Maurizio Vecchi; Alberto Malesci; Max Reinshagen; Robert Löfberg
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

Review 3.  Leucocytapheresis for inflammatory bowel disease in the era of biologic therapy.

Authors:  Hiroyuki Hanai
Journal:  Eur J Gastroenterol Hepatol       Date:  2008-07       Impact factor: 2.566

Review 4.  Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.

Authors:  Hiroyuki Hanai
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

5.  Leukocytapheresis is effective in inducing but not in maintaining remission in ulcerative colitis.

Authors:  Terasu Honma; Kazuhito Sugimura; Hitoshi Asakura; Jun Matsuzawa; Kohji Suzuki; Masaaki Kobayashi; Yutaka Aoyagi
Journal:  J Clin Gastroenterol       Date:  2005 Nov-Dec       Impact factor: 3.062

6.  Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients.

Authors:  K Takemoto; J Kato; M Kuriyama; T Nawa; M Kurome; H Okada; K Sakaguchi; Y Shiratori
Journal:  Dig Liver Dis       Date:  2007-03-26       Impact factor: 4.088

7.  Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.

Authors:  R D Cohen
Journal:  Inflamm Bowel Dis       Date:  2001-05       Impact factor: 5.325

8.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

9.  Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study.

Authors:  Yasuhisa Sakata; Ryuichi Iwakiri; Sadahiro Amemori; Kanako Yamaguchi; Takehiro Fujise; Hibiki Otani; Ryo Shimoda; Seiji Tsunada; Hiroyuki Sakata; Yuji Ikeda; Takashi Ando; Yuji Nakafusa; Kazuma Fujimoto
Journal:  Eur J Gastroenterol Hepatol       Date:  2008-07       Impact factor: 2.566

10.  Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study.

Authors:  Yasuo Suzuki; Naoki Yoshimura; Abby R Saniabadi; Yasushi Saito
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

View more
  4 in total

1.  Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry.

Authors:  J L Cabriada; E Domènech; N Ibargoyen; V Hernández; J Clofent; D Ginard; I Gutiérrez-Ibarluzea; J Hinojosa
Journal:  J Gastroenterol       Date:  2011-11-23       Impact factor: 7.527

2.  Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease.

Authors:  Chiara De Cassan; Edoardo Savarino; Piero Marson; Tiziana Tison; Giorgia Hatem; Giacomo Carlo Sturniolo; Renata D'Incà
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

3.  A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis.

Authors:  Takayuki Yamamoto; Takayuki Iida; Kentaro Ikeya; Masaichi Kato; Ai Matsuura; Satoshi Tamura; Ryosuke Takano; Shinya Tani; Satoshi Osawa; Ken Sugimoto; Takahiro Shimoyama; Hiroyuki Hanai
Journal:  Clin Transl Gastroenterol       Date:  2018-07-06       Impact factor: 4.488

Review 4.  Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective.

Authors:  Eugeni Domènech; Joan-Ramon Grífols; Ayesha Akbar; Axel U Dignass
Journal:  World J Gastroenterol       Date:  2021-03-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.